文献速递消化道肿瘤放疗

输注5-氟尿嘧啶联合吉非替尼联术前放疗治疗直肠癌的I期和II期试验:中位随访10年

Phase I and II trial on infusional 5-fluorouracil and gefitinib in combination with preoperative radiotherapy in rectal cancer: 10-years median follow-up.
PubMed 文献 · Clin Transl Radiat Oncol · 2018-03-17

PURPOSE: The aim of this study is to evaluate the long term survival of the addition of gefitinib to chemoradiotherapy (CRT) in locally advanced rectal cancer (LARC).…

要点

  • 中位随访133个月,5年局部控制率84%、无转移生存率71%、无病生存率64%、总生存率87%、疾病特异生存率92%。

核心结论

  • 长期结局和晚期毒性与既往报道系列相似,加用吉非替尼未改善局部晚期直肠癌的结局。
  • 不推荐吉非替尼用于接受5-FU为基础术前放化疗的直肠癌患者。
  • 进一步研究可能识别吉非替尼是否对特定患者组有益。

研究设计与样本

  • 多中心、开放标签、I-II期研究,纳入局部晚期直肠癌患者。
  • 患者接受5-氟尿嘧啶持续静脉输注联合口服吉非替尼剂量递增的放化疗,6-8周后手术。
  • 计划术中放疗加量10 Gy,ypN1-2患者接受辅助化疗。
  • 初始入组41例患者,39例可评估(27例男性,12例女性)。
  • 中位随访133个月,分析局部控制、无转移生存、无病生存、疾病特异生存和总生存,并通过单因素和多因素分析检验预测终点。

主要发现

  • 5年局部控制率84%、无转移生存率71%、无病生存率64%、总生存率87%、疾病特异生存率92%。
  • 分析变量包括年龄、吉非替尼剂量和中断、辅助化疗、手术类型、ypT、ypN和TRG分级。

关键数值与推荐

  • 5年局部控制率84%、无转移生存率71%、无病生存率64%、总生存率87%、疾病特异生存率92%。

临床怎么用

  • 原文结论为不推荐吉非替尼用于接受5-FU为基础术前放化疗的直肠癌患者。
  • 原文未据此给出其他临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study is to evaluate the long term survival of the addition of gefitinib to chemoradiotherapy (CRT) in locally advanced rectal cancer (LARC). METHODS AND MATERIALS: This previously published multicentre, open-label, phase I-II study, enrolled patients (pts) with LARC to receive CRT with concurrent 5-fluorouracil continuous intravenous infusion and a dose escalation of orally administered gefitinib, followed 6-8 weeks later by surgery. An intra-operative radiotherapy boost of 10 Gy was planned. Adjuvant chemotherapy was administrated in ypN1-2 pts. After a median f/u of >10 years, we analyzed Local Control (LC), Metastasis Free Survival (MFS), Disease Free Survival (DFS), Disease Specific Survival (DSS) and Overall Survival (OS). Predictive endpoints of clinical outcomes were tested by univariate and multivariate analysis. Variables analyzed included: age, gefitinib dose and interruptions, adjuvant CT, surgery type, ypT, ypN, and TRG grade. We have also analyzed late toxicity according to CTCAEv4. RESULTS: Of the 41 initially enrolled pts, 39 were evaluable (27M, 12F). With a median f/u of 133 months, LC, MFS, DFS, OS and DSS at 5 years were 84%; 71%; 64%; 87% and 92%, respectively. The OS and DSS at 10 years were 61,5% and 76%, respectively. Grade 3-4 late toxicity occurred in 38% of pts: sexual (28,2%) and gastrointestinal toxicities (10,2%). CONCLUSION: Long term outcomes and late toxicity were similar to previously reported series. The addition of gefitinib did not improve outcomes in LARC. Gefitinib is not recommended for rectal cancer patients who received 5-FU based preoperative CRT. Further studies may identify if gefitinib is beneficial in selected group of patients.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Gambacorta MA, De Paoli A, Lupattelli M, et al. Phase I and II trial on infusional 5-fluorouracil and gefitinib in combination with preoperative radiotherapy in rectal cancer: 10-years median follow-up. Clin Transl Radiat Oncol. 2018. PMID: 29928702. doi:10.1016/j.ctro.2018.02.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。